Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.83 AUD
Change Today -0.03 / -3.51%
Volume 149.4K
BLT On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
OTC US
As of 2:10 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

benitec biopharma ltd (BLT) Snapshot

Open
A$0.87
Previous Close
A$0.86
Day High
A$0.87
Day Low
A$0.83
52 Week High
05/20/14 - A$1.42
52 Week Low
10/30/14 - A$0.52
Market Cap
95.6M
Average Volume 10 Days
135.9K
EPS TTM
A$-0.09
Shares Outstanding
115.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BENITEC BIOPHARMA LTD (BLT)

Related News

No related news articles were found.

benitec biopharma ltd (BLT) Related Businessweek News

No Related Businessweek News Found

benitec biopharma ltd (BLT) Details

Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company’s ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington’s disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.

13 Employees
Last Reported Date: 08/22/14
Founded in 1997

benitec biopharma ltd (BLT) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$450.0K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$267.4K
Chief Business Officer
Total Annual Compensation: A$302.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: A$305.1K
Chief Scientific Officer
Total Annual Compensation: A$225.0K
Compensation as of Fiscal Year 2014.

benitec biopharma ltd (BLT) Key Developments

Benitec Biopharma Doses Fifth Patient and Initiates Additional Trial Site For Hepatitis C Trial

Benitec Biopharma advised that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has been dosed at the Duke Clinical Research Unit. The fifth patient is the third and final patient to be dosed in Cohort 2. The three patients in Cohort 2 received a dose of TT-034 of 1.25 x 10^11 vg/kg, a concentration that is a half log higher than the doses administered in Cohort 1. In line with the trial's primary endpoint of safety, this dose level is still below the concentration expected to inhibit HCV viral replication and data from the second dosing cohort is therefore expected to serve primarily as a further safety assessment. As with previous patients, the newly dosed patient will be monitored for six weeks and this data will then be reviewed by the Data Safety Monitoring Board (DSMB). Benitec is currently screening patients for inclusion in cohort 3 in anticipation of the DSMB's review. Benitec has now initiated a third site, the Texas Liver Institute in San Antonio, Texas, and they have started to pre-screen patients for the TT-034 trial. Following completion of the first two patient cohorts and initiation of a third trial site, Benitec will now move to conventional clinical trial reporting for cohorts 3 through to 5 of the dose escalation study.

Benitec Biopharma Limited Provides Update on TT-034 Trial

Benitec Biopharma Limited announced that TT-034 works by producing (in the liver) three silencing short hairpin RNAs (shRNAs), each responsible for targeting a different part of the hepatitis C virus' genome. The expression of the three shRNAs in patients' liver cells is thus an essential requirement for TT-034 to exert a clinical reduction of hepatitis C viral load. These results were obtained from the biopsies of the first two patients in cohort 1 and the first patient in cohort 2. The second patient in cohort 2 has not yet been biopsied, and the third patient in cohort 2 is yet to be dosed due to a personal issue. In cohorts 1 and 2, the dose of TT-034 is sub-therapeutic and, therefore, the amount of shRNA produced will not result in reduction of hepatitis C viral load.

Benitec Biopharma Limited Doses Fourth Patient in Hepatitis C Trial

Benitec Biopharma Limited announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. This is the second patient to be dosed in Cohort Two, with the third and final patient in Cohort Two well advanced in their preparation for dosing. The parallel dosing of these patients follows a positive recommendation from the DSMB's review of the safety data from the first patient in this cohort. All three patients in Cohort Two receive a dose of 1.25 x 10^11 vg/kg of TT-034, a concentration that is a half-log higher than the dose administered in Cohort One. This dose level is still below the concentration expected to inhibit hepatitis C viral replication and therefore data from Cohort Two are expected to serve primarily as a further safety assessment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLT:AU A$0.83 AUD -0.03

BLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Galena Biopharma Inc $1.34 USD -0.05
Marina Biotech Inc $0.57 USD 0.0001
Regulus Therapeutics Inc $12.76 USD -0.69
Silence Therapeutics PLC 302.00 GBp -2.00
View Industry Companies
 

Industry Analysis

BLT

Industry Average

Valuation BLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.9x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BENITEC BIOPHARMA LTD, please visit www.benitec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.